Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CADL
SellCandel Therapeutics, Inc. · Healthcare · United States · $1.0B · Avg Vol: $16M/d
COMPANY DESCRIPTION
Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0.1M | 0 | 0 | 0 | — | — | — | 43.4M | 222.2% |
| EPS | -1.91 | -0.26 | -0.52 | -1.74 | -0.72 | — | -1.47 | -1.00 | -0.63 | — |
| Shares | — | 73.3M | 73.3M | 46.8M | 54.9M | -25.1% | — | — | — | — |
| Debt | — | 22.8M | 22.8M | 13.5M | 49.0M | 29.1% | 49.5M | — | — | — |
| Equity | — | 47.7M | 12.7M | 66.3M | 51.9M | 2.9% | — | — | — | — |
| Op CF | — | -31.4M | -34.2M | -27.0M | -38.3M | — | -56.0M | — | — | — |
| Inv CF | — | -1.3M | -0.3M | -16.0K | -0.6M | — | — | — | — | — |
| Fin CF | — | 20.0M | -0.1M | 94.3M | 56.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CADL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc.(you) | $1.0B | 31 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 34 | Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 29 | Sell |
| FTH | Faeth Therapeutics, Inc. | $874M | 32 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 34 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 34 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 29 | Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 27 | Sell |
| SLDB | Solid Biosciences Inc. | $1.0B | 38 | Hold |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%